Furthermore, there remains a significant proportion of missing data in LV function assessment post-STEMI, alongside the absence of any additional detailed metrics of heart failure, alongside a lack of data regarding titration of heart failure therapy, especially newer agents such as SGLT2 inhibitors or ARNIs. This evidence concerns the gene SLC5A2 and heart failure.